NeuroSense Therapeutics (NRSN) Competitors $1.17 -0.08 (-6.40%) Closing price 08/14/2025 04:00 PM EasternExtended Trading$1.17 0.00 (-0.09%) As of 08/14/2025 06:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock NRSN vs. INMB, STRO, GNTA, ARTV, FBRX, IMMX, MNOV, RPTX, PYXS, and ATRAShould you be buying NeuroSense Therapeutics stock or one of its competitors? The main competitors of NeuroSense Therapeutics include INmune Bio (INMB), Sutro Biopharma (STRO), Genenta Science (GNTA), Artiva Biotherapeutics (ARTV), Forte Biosciences (FBRX), Immix Biopharma (IMMX), MediciNova (MNOV), Repare Therapeutics (RPTX), Pyxis Oncology (PYXS), and Atara Biotherapeutics (ATRA). These companies are all part of the "pharmaceutical products" industry. NeuroSense Therapeutics vs. Its Competitors INmune Bio Sutro Biopharma Genenta Science Artiva Biotherapeutics Forte Biosciences Immix Biopharma MediciNova Repare Therapeutics Pyxis Oncology Atara Biotherapeutics NeuroSense Therapeutics (NASDAQ:NRSN) and INmune Bio (NASDAQ:INMB) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, earnings, dividends, institutional ownership, media sentiment, risk and profitability. Which has preferable valuation & earnings, NRSN or INMB? NeuroSense Therapeutics has higher earnings, but lower revenue than INmune Bio. NeuroSense Therapeutics is trading at a lower price-to-earnings ratio than INmune Bio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNeuroSense TherapeuticsN/AN/A-$10.21M-$0.54-2.17INmune Bio$10K6,512.10-$42.08M-$2.48-0.99 Which has more volatility & risk, NRSN or INMB? NeuroSense Therapeutics has a beta of 1.64, meaning that its share price is 64% more volatile than the S&P 500. Comparatively, INmune Bio has a beta of 0.97, meaning that its share price is 3% less volatile than the S&P 500. Is NRSN or INMB more profitable? NeuroSense Therapeutics' return on equity of 0.00% beat INmune Bio's return on equity.Company Net Margins Return on Equity Return on Assets NeuroSense TherapeuticsN/A N/A -445.40% INmune Bio N/A -120.62%-92.94% Do analysts recommend NRSN or INMB? NeuroSense Therapeutics presently has a consensus price target of $14.00, indicating a potential upside of 1,096.58%. INmune Bio has a consensus price target of $18.40, indicating a potential upside of 651.02%. Given NeuroSense Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe NeuroSense Therapeutics is more favorable than INmune Bio.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NeuroSense Therapeutics 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.00INmune Bio 1 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.57 Does the media favor NRSN or INMB? In the previous week, INmune Bio had 5 more articles in the media than NeuroSense Therapeutics. MarketBeat recorded 7 mentions for INmune Bio and 2 mentions for NeuroSense Therapeutics. INmune Bio's average media sentiment score of 0.85 beat NeuroSense Therapeutics' score of 0.43 indicating that INmune Bio is being referred to more favorably in the news media. Company Overall Sentiment NeuroSense Therapeutics Neutral INmune Bio Positive Do insiders & institutionals believe in NRSN or INMB? 1.0% of NeuroSense Therapeutics shares are owned by institutional investors. Comparatively, 12.7% of INmune Bio shares are owned by institutional investors. 27.4% of NeuroSense Therapeutics shares are owned by insiders. Comparatively, 35.7% of INmune Bio shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. SummaryINmune Bio beats NeuroSense Therapeutics on 8 of the 14 factors compared between the two stocks. Get NeuroSense Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for NRSN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NRSN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NRSN vs. The Competition Export to ExcelMetricNeuroSense TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$17.08M$3.10B$5.62B$9.84BDividend YieldN/A2.23%4.61%4.07%P/E Ratio-2.1720.4930.2925.74Price / SalesN/A356.37463.41115.83Price / CashN/A43.0338.2159.48Price / Book-29.258.608.826.15Net Income-$10.21M-$54.65M$3.25B$265.06M7 Day Performance-7.14%5.86%3.71%2.60%1 Month Performance-40.91%8.86%5.85%2.83%1 Year Performance58.11%13.33%29.92%25.58% NeuroSense Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NRSNNeuroSense Therapeutics2.4005 of 5 stars$1.17-6.4%$14.00+1,096.6%+67.1%$17.08MN/A-2.1710Short Interest ↑INMBINmune Bio2.3526 of 5 stars$2.40-6.3%$18.40+666.7%-63.6%$68.06M$10K-0.9710STROSutro Biopharma4.2192 of 5 stars$0.77-3.7%$6.11+691.4%-78.3%$68.02M$62.04M-0.31240News CoverageEarnings ReportAnalyst ForecastGNTAGenenta Science2.7901 of 5 stars$3.54-4.7%$25.00+607.2%-23.8%$67.87MN/A0.007Positive NewsGap UpHigh Trading VolumeARTVArtiva Biotherapeutics2.7513 of 5 stars$2.56-7.2%$17.80+595.3%-76.4%$67.42M$250K0.0081FBRXForte Biosciences2.633 of 5 stars$10.51+3.2%$61.00+480.4%+69,259.0%$66.99MN/A-0.655Earnings ReportGap DownIMMXImmix Biopharma3.6294 of 5 stars$2.32-2.9%$7.00+201.7%+15.9%$66.63MN/A-3.019Earnings ReportMNOVMediciNova2.4559 of 5 stars$1.33-1.5%$7.00+426.3%+15.0%$66.21M$1M-5.7810Gap DownRPTXRepare Therapeutics2.8038 of 5 stars$1.54+0.3%$4.50+192.2%-44.7%$65.84M$53.48M-0.60180Earnings ReportPYXSPyxis Oncology2.3726 of 5 stars$1.04-1.9%$8.67+733.3%-66.4%$65.67M$16.15M-0.6560News CoverageEarnings ReportGap DownHigh Trading VolumeATRAAtara Biotherapeutics4.6218 of 5 stars$10.32-5.8%$20.00+93.8%+51.8%$65.31M$128.94M-2.77330Positive NewsEarnings Report Related Companies and Tools Related Companies INMB Competitors STRO Competitors GNTA Competitors ARTV Competitors FBRX Competitors IMMX Competitors MNOV Competitors RPTX Competitors PYXS Competitors ATRA Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NRSN) was last updated on 8/15/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NeuroSense Therapeutics Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share NeuroSense Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access